Human genetic studies have been successfully used to identify genes and pathways relevant to human biology. Using genetic instruments composed of loci associated with human lipid traits, recent studies have begun to clarify the causal role of major lipid fractions in risk of cardiometabolic disease.
INTRODUCTION
Several pragmatic motivating factors continue to encourage ongoing human genetic studies focused on resolving the complete genetic architecture of plasma lipid traits. First, every locus identified for these traits has the potential -when resolved to causal variant(s) and gene(s) -to contribute to our understanding of the biology underlying lipoprotein metabolism in humans [1, 2] . Importantly, some loci will emerge from these studies as potential targets for therapeutically manipulating plasma lipids [3, 4] . Finally, resolving the full contribution of rare and common alleles to these traits also has substantial implications for genetic diagnoses in the dawning era of precision medicine.
Considerable progress has already been made in identifying genetic loci that are robustly associated with variability in plasma lipids. In the most recent genome-wide association study (GWAS) by the Global Lipids Genetics Consortium, which included nearly 187 000 individuals, investigators identified 157 independent genetic loci which were significantly associated with at least one of four major lipid fractions: total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides [1] . Two observations may lead some to speciously question the utility of performing additional gene-mapping studies to identify new loci and resolve existing association signals: current studies only explain a small fraction of the population variance in the trait, despite already substantial sample sizes (leading some to wonder if this is the correct approach), and each novel locus is typically associated with increasingly smaller effects on the trait (otherwise the association would likely have been previously identified). If the goal of trait mapping is to understand biology and identify therapeutic targets, however, the variance attributable to either individual or the sum of all loci together is irrelevant. For example, a common variant (rs17238484) in the HMG Co-A reductase gene (HMGCR) has a very modest effect on LDL cholesterol in the population (1.08 mg/dl lower LDL cholesterol for each copy of the minor allele) [5 & ]. Similarly, gain-of-function variants in PCSK9 were identified as a cause of autosomal dominant hypercholesterolemia [3] ; these specific variants contribute to nearly zero population variance due to their rarity. Despite this, HMGCR and PCSK9 are key elements in the biological pathways of cholesterol biosynthesis and metabolism, and substantially effect plasma LDL levels when therapeutically manipulated [6, 7] .
Multiple approaches can be used to identify additional loci underlying plasma lipids and to refine the signals within existing loci. In addition to merely increasing sample size (the most obvious means of augmenting statistical power), recent studies have leveraged denser imputation panels [8, 9] , studied populations with different or unique genetics [10, 11] , and ascertained families with extreme phenotypes [12] [13] [14] , all of which have enriched our understanding of human lipoprotein metabolism.
In addition to furthering our knowledge of basic human biology, human genetics has the potential to identify causal mechanisms for disease. From a therapeutic perspective, it is obviously critical to understand the relationship between genetic loci and risk of disease, as therapeutic manipulation of plasma lipid levels is not a goal unto itself, but rather a means to alter disease. Several studies, reviewed below, have contributed to our understanding of lipoprotein metabolism and risk of cardiometabolic disease.
HUMAN GENETIC INSIGHTS INTO THE ROLE OF PLASMA LIPIDS AND CORONARY ARTERY DISEASE
Over 50 years ago, investigators at the Framingham study identified plasma cholesterol as a 'factor of risk' for the development of coronary heart disease [15] ; subsequent basic science investigation [16] and clinical trial results [6] have firmly established elevated LDL cholesterol as a causal risk factor for coronary artery disease. Prior studies identifying genetic variation in PCSK9 that associated with both altered LDL cholesterol and risk of coronary disease [4] have successfully accelerated therapeutic development [17, 18] (e.g. PCSK9 loss-of-function variants); several recent human genetic studies have contributed to this effort of identifying genetic variation that associates with lipid traits and risk of coronary disease.
Genetic variation modulating LDL cholesterol and risk of coronary artery disease
Nioi et al. [19 & ] undertook such a study in which the investigators started with whole genome sequencing (WGS) in 2636 Icelanders. They imputed the variants discovered by WGS into 119 146 participants with lipid measurements and identified several correlated single-nucleotide polymorphisms (SNPs) that were strongly associated with non-HDL cholesterol and that spanned the genes ASGR1 and ASGR2, encoding subunits of the asialoglycoprotein receptor. Nioi et al. observed that an intron of ASGR1 had low WGS coverage likely due to local sequence context, and performed additional sequencing in this low coverage area. This led to the discovery of a 12-bp intronic deletion in ASGR1, which appeared to be responsible for the statistical association between this locus and non-HDL cholesterol. The 12-bp deletion, which causes aberrant mRNA splicing and the subsequent synthesis of a truncated ASGR1 protein, was significantly associated with reduced levels of non-HDL cholesterol (À15.3 mg/dl for carriers), which appeared to be primarily due to lower LDL cholesterol in carriers (À12.5 mg/dl for carriers). Beyond an association with non-HDL cholesterol, the investigators also
KEY POINTS
Human genetic studies have identified hundreds of loci associated with plasma lipid traits, which have informed our understanding of the biology underlying lipoprotein metabolism in humans.
Several specific genetic mechanisms that alter plasma lipids and risk of coronary artery disease have now been identified, highlighting potential therapeutic targets.
Current studies support a causal role in coronary artery disease for LDL cholesterol in addition to cholesterol found in lipoproteins other than HDL cholesterol.
Lowering LDL cholesterol through multiple mechanisms increases risk for type 2 diabetes.
Genetically elevated HDL cholesterol and triglycerides are associated with lower risk of type 2 diabetes, although this relationship may be dependent on specific mechanisms.
demonstrated that carriers had a 34% reduced risk of coronary disease compared with noncarriers. Somewhat intriguingly, the 12-bp ASGR1 deletion was associated with a reduction in coronary disease risk beyond what one might expect based solely on the magnitude of the decrease in non-HDL cholesterol (this comparison was performed using genetic associations in other genes affecting non-HDL cholesterol and coronary disease risk), suggesting there may be nonlipid atheroprotective effects associated with loss of ASGR1.
In addition to identifying potentially novel targets, a human genetic approach can be used to support existing therapeutic targets. We used this type of approach to demonstrate that loss-of-function mutations in the Niemann-pick C1-like 1 (NPC1L1) gene were associated with a reduced risk of coronary artery disease [20] . Despite being approved for therapeutic use in many countries, there was substantial uncertainty over whether or not ezetimibe (a nonstatin medication that reduces plasma LDL cholesterol by inhibiting NPC1L1) would reduce coronary artery disease [21, 22] . To address this question, we sequenced NPC1L1 and found that approximately 1 in every 650 individuals carried a loss-of-function allele in NPC1L1. These individuals, when compared with those who did not carry NPC1L1 inactivating mutations, had approximately 12 mg/dl lower LDL cholesterol and 53% reduced risk of coronary artery disease [20] . A large randomized control trial later demonstrated that therapeutic inhibition of NPC1L1 with ezetimibe resulted in lower LDL cholesterol and a significant reduction in risk of recurrent coronary disease [23] . Other protein-altering variants associated with LDL cholesterol and risk of coronary artery disease are listed in Table 1 .
Are HDL cholesterol and triglycerides causal factors for coronary artery disease?
Beyond LDL cholesterol, human genetics has the potential to identify lipid fractions that are causally related to coronary disease and genes and/or pathways that associate with both causal fractions and risk of disease. Whereas LDL cholesterol has been accepted as a causal factor for coronary artery disease, the epidemiological data implicating HDL and triglyceride as causal factors were unclear. HDL and triglycerides are negatively correlated in population studies and both are correlated with coronary artery disease [30] . The relationship between triglycerides and coronary disease typically disappears, however, when HDL cholesterol is accounted for [30] , leading some prior studies to conclude that HDL cholesterol was the likely causal fraction of the two. These types of studies are prone to confounding, however, and approaches using the technique of Mendelian randomization have attempted to address this question for HDL and triglyceride-rich lipoproteins (TRLs) [31 && ,32,33] . Whereas previous studies have typically focused on SNPs identified in GWAS studies (in which case most SNPs are of common frequency in the population), Helgadottir et al. [34] recently extended this approach to include lowfrequency and rare variants that they discovered to associate with lipid fractions. First, using the same lipid associations as were used in the study by Nioi et al. [19 & ] discussed above, Helgadottir et al. created a genetic risk score (GRS) of associated variants for Although perhaps a subtle distinction, clarifying this mechanistically may have important implications for future therapeutic development. For example, approaches focused on modifying the triacylglycerol content in TRLs may not be as effective for treating coronary disease as lowering total TRL concentration (which would reduce both triacylglycerols and cholesterol content in the plasma). Further development in this area is needed to clarify these points.
Current human genetic evidence is coalescing around lipoprotein lipase (LPL) as one potential mechanism for altering TRL concentration in a manner that alters coronary disease risk, beginning with the observation that loss-of-function mutations in APOC3 were associated with lower concentrations of TRLs and reduced risk of coronary disease [24, 25] . APOC3 is an endogenous inhibitor of LPL, the latter of which functions to hydrolyze triglycerides present in circulating lipoproteins, thereby lowering plasma TRL concentration. As an endogenous inhibitor of LPL, loss of APOC3 function should result in higher LPL activity and loss of an endogenous activator of LPL should result in the opposite effects. Do et al. [26 & ], after sequencing the exomes of nearly 10 000 individuals with and without coronary disease, discovered loss-of-function variants in apolipoprotein A-V (APOA5) -an endogenous LPL activator -were associated in a manner that one would expect, where loss of APOA5 associated with higher triglycerides and increased risk of coronary disease. These observations appear to be somewhat generalizable, as loss of function in an additional endogenous LPL inhibitor (ANGPTL4) was recently found to associate with reductions in plasma TRLs and lower risk of coronary disease [27 & ]. Similarly, these findings are not limited just to regulatory proteins, as loss and gain-of-function variants in the LPL gene itself are associated with the a priori expected alteration in TRL concentration and risk of coronary disease [27 & ]. This allelic series in LPL and its endogenous regulators, in which loss and gain of gene function modulate both the biomarker and risk of disease in the expected direction of effect, increases the confidence in this pathway as a potential target for therapeutic intervention [35] . A partial listing of other protein-altering variants associated with altered plasma lipids and risk of coronary artery disease is provided in Table 1 .
HUMAN GENETIC INSIGHTS INTO THE ROLE OF PLASMA LIPIDS AND TYPE 2 DIABETES
HMG-Co-A reductase, LDL cholesterol, and risk of diabetes As mentioned above, the relationship between plasma lipid traits and coronary disease has been long recognized. Similarly, prior studies have found a relationship between increased risk of type 2 diabetes with reduced HDL cholesterol and elevated triglyceride concentrations (without any such observation for LDL cholesterol) [36] [37] [38] . Despite the epidemiological lack of association between LDL cholesterol and risk of diabetes, therapeutic trials of statin medications (which lower LDL cholesterol) have consistently shown an increased risk of diabetes among statin-treated patients compared with those on placebo [39] . Whether or not the increased diabetic risk was due to an off-target effect of statins, an artifact of study design, chance, or numerous other possibilities was debated until a study by Swerdlow et al. [5 & ] provided human genetic evidence to suggest it was due to an 'on-target' effect of statins. By studying genetic variation in HMGCR, Swerdlow et al. were able to demonstrate that the same genetic variants in HMGCR that associated with reduced LDL cholesterol were also associated with increased risk of type 2 diabetes. This result suggests that the increased risk of type 2 diabetes associated with statin use is not due to an off-target effect from statins, but rather is from inhibiting HMGCR. Furthermore, their result suggests that further efforts to make statins more specific in an attempt to reduce diabetes risk may be futile [40] . Importantly, these same variants are also associated with lower risk of coronary artery disease, suggesting that even though statin therapy appears to increase the risk of type 2 diabetes by inhibiting HMGCR, the net LDL-lowering effect of this mechanism is atheroprotective.
Genetic variation modulating LDL cholesterol and risk of type 2 diabetes
The degree to which this effect extended to other LDL-lowering mechanisms remained unclear until a recent study by Lotta et al. [41 && ]. In this study, genetic variants in multiple LDL-associated genes were evaluated for an effect on both type 2 diabetes and coronary artery disease. Similar to Swerdlow et al., Lotta et al. found that the genetic variants in HMGCR that were associated with lower LDL cholesterol were also associated with lower coronary artery disease risk, but higher risk of type 2 diabetes. Beyond HMGCR, Lotta et al. observed similar effects for genetic variants in NPC1L1, ABGC5/ABGC8, and PCSK9 (all current or potential lipid-modifying targets) in which the variants associated with lower LDL cholesterol were also associated with lower coronary artery disease risk, but increased risk of type 2 diabetes. The finding that LDL lowering not just by HMGCR and statins but also by multiple drug target genetic mechanisms is associated with increased risk of type 2 diabetes and has important implications for therapeutic development and future clinical trials.
Are HDL cholesterol and triglycerides causal factors for type 2 diabetes?
Beyond drugs focused on LDL cholesterol, will therapies focused on TRLs also affect risk of type 2 diabetes? White et al. [42] recently employed a Mendelian randomization technique to estimate the causal role of lipid fractions in risk of diabetes. Using genetic instruments consisting of SNPs associated with LDL cholesterol, HDL cholesterol, and triglycerides, the investigators calculated the association between genetically higher lipid levels and both risk of coronary artery disease and type 2 diabetes. Consistent with the results of Lotta et al., White et al. found that genetically elevated LDL cholesterol was associated with reduced risk of type 2 diabetes. Beyond LDL cholesterol, they found that both genetically elevated HDL cholesterol and triglycerides were associated with reduced risk of type 2 diabetes (see Table 2 ). The result that genetically elevated triglyceride concentrations associate with reduced risk of type 2 diabetes is surprising [48] and, due to important implications if valid, deserves further study.
It is important to note, however, that the approach of White et al. is designed to study the biomarker generally and does not necessarily apply to specific genetic mechanisms. Unlike LDL cholesterol, for which Lotta et al. demonstrate is causally related to type 2 diabetes across multiple genetic mechanisms, the HDL cholesterol and triglyceride association with type 2 diabetes may be dependent on specific mechanisms. For example, whereas genetically elevated HDL cholesterol in general appears to be protective for type 2 diabetes, Clapham et al. [49] did not find an association for diabetes with a null allele in ANGPTL8 that associated with higher HDL cholesterol, although it is interesting to note that there was a nonsignificant trend toward protection. Similarly, whereas the evidence is clear that HDL cholesterol in general is not causal for coronary disease, specific mechanisms that alter HDL cholesterol may affect risk of disease [13] . Finally, we found that a loss-of-function variant in ANGPTL4, which associated with reduced TRL and lower risk of coronary artery disease, was also nominally associated with a reduction in risk of diabetes [27 & ], raising the possibility that certain mechanisms resulting in reduced TRL (such as modulators of LPL activity, for example) may protect against both coronary artery disease, and also type 2 diabetes.
CONCLUSION
With advances in the scale and content of human genetic studies, our view of the genetic architecture Increased [42] No evidence
Genetic estimate refers to Mendelian randomization studies including multiple genetic variants affecting the trait. RCT evidence indicates results from randomized control trials of drugs focused primarily on modifying that lipid fraction.
underlying plasma lipid biology is coming increasingly into focus. Armed with these tools, investigators are expanding the focus of these studies in new and creative ways to investigate the net cardiometabolic effects of lipoprotein metabolism. Results of these and future studies are poised to provide important insights into the causal relationship between these traits and disease, and should highlight important mechanisms for novel therapeutic development.
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